Related Experiment Videos
Nephrotoxicity associated with cyclosporine and FK506
1Baylor University Medical Center, Dallas, TX 75246, USA.
Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
|September 1, 1995
Abstract:
In conclusion, nephrotoxicity is a common and potentially clinically significant problem with cyclosporine and FK506 following transplantation. Further definition of its pathogenesis and improved dosing strategies for both of these drugs may reduce the impact of nephrotoxicity on both short-term and long-term outcomes.
Insights
Nephrotoxicity is a common issue with cyclosporine and FK506 after transplantation. Understanding how these drugs harm kidneys and optimizing their dosage can improve patient outcomes.
Area of Science:
- Nephrology
- Immunosuppression Pharmacology
Background:
- Nephrotoxicity is a significant clinical challenge associated with immunosuppressive drugs.
- Cyclosporine and FK506 are widely used post-transplantation but carry risks of kidney damage.
Purpose of the Study:
- To highlight the prevalence and clinical importance of nephrotoxicity.
- To emphasize the need for further research into drug-induced kidney injury.
Main Methods:
- Literature review on cyclosporine and FK506 nephrotoxicity.
- Analysis of clinical significance and patient outcomes.
Main Results:
- Nephrotoxicity is a frequent complication in transplant recipients.
- This kidney damage impacts both short-term and long-term patient health.
Conclusions:
- Further research into the pathogenesis of nephrotoxicity is crucial.
- Optimizing dosing strategies for cyclosporine and FK506 may mitigate kidney damage and improve transplant success.